Can­cer drug prices rise in the US de­spite an in­creas­ing­ly com­pet­i­tive mar­ket — re­port

As De­moc­rats’ hopes of Medicare drug price ne­go­ti­a­tions seem fur­ther out of reach, a new study shows that in­creased com­pe­ti­tion in the can­cer drug mar­ket has not, in fact, led to price de­creas­es — well, not in the US at least.

Be­tween 2009 and 2020, prices in­creased — with one ex­cep­tion — with­in and across all 12 can­cer drug class­es stud­ied in the US, where­as prices in Switzer­land and Ger­many gen­er­al­ly de­creased over time or did not rise more than in­fla­tion, ac­cord­ing to a re­cent pub­li­ca­tion in the Lancet. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER